Special Funding Requests (Third Round Funding)

The AI Gigafactories Call is the largest single AI funding instrument in Europe and one of the least like a grant. EuroHPC JU is not funding research projects; it is co-investing in the construction of up to seven physical facilities that combine massive computing power with state-of-the-art AI processors, the necessary software and cloud technology stacks, high-bandwidth connectivity and energy-efficient data centres, to provide frontier AI training, fine-tuning and inference as sovereign European services. The applicant profile follows from that: applications are open to consortia or Special Purpose Vehicles bringing together companies, public entities, investors and other partners, and a facility may sit within a single Member State or be distributed across several. This is a call for infrastructure developers and capital syndicates, not for research groups. The financial structure is co-funding rather than full funding - successful projects receive differing levels of EU and national support reflecting the size and range of sovereign services they commit to provide, against an EU and national envelope of up to 10,000,000,000 euros that is expected to mobilise at least 20,000,000,000 euros of private investment. The timeline is long and worth planning around: the submission deadline is 12 November 2026, competitive evaluation follows, selections are expected in early 2027, and operations are to commence within 18 months of selection. Note that the AI Gigafactories are a tier above the existing AI Factories - EuroHPC currently oversees 19 AI Factories and 13 AI Factory Antennas that provide free access to SMEs and startups - so organisations wanting to use European AI compute rather than build it should look to the AI Factories access calls instead. Submission is through the EU Tenders and Funding Portal.

Summary: The fiscal year 2026 (FY26) Joint Warfighter Medical Research Program (JWMRP) Military Medical Research and Development Award (MMRDA) mechanism is intended to fund the logical continuation of previous Department of War (DOW)-funded research and development efforts relevant to the FY26 JWMRP that augment and accelerate high-priority medical requirements to meet the needs of Service Members and other Military Health System beneficiaries. The MMRDA supports a wide range of research projects spanning late-stage preclinical studies, late-state technology development efforts, technology demonstration, translational, and clinical research. Projects must be relevant to at least one of the FY26 JWMRP focus areas.Distinctive Features:To be eligible for JWMRP funding, applicants/offerors must have already received DOD/DOW core or DOD/DOW Congressional Special Interest funding.An MMRDA Clinical Research or Clinical Trial Option (MMRDA-CRCTO) is available to specifically support clinical research/observational studies, all phases of clinical trials/interventional studies, and/or correlative studies in support of the development of promising pharmaceutical or biologic candidates, medical devices and technologies. Applicants/offerors should select MMRDA-CRCTO when the application/proposal involves research that includes any human subjects, human biological samples (prospective or retrospective) or human data sets. Note: If selecting this option, applicants must submit additional relevant application/proposal materials. Funding Opportunity Number: HT942526JWMRPMMRDA. Assistance Listing: 12.420. Funding Instrument: CA,G,O,PC. Category: ST. Award Amount: $8.8M total program funding.